Table 6.
Clinical Trials with Belinostat in Combination with Other Drug/Regimens
| NCT number | Recruitment | Conditions | Interventions | Phases | Funded by |
|---|---|---|---|---|---|
| NCT01075425 | Recruiting | ALL|AML|MDS|CML | Bortezomib|Belinostat | 1 | Other|NIH |
| NCT00421889 | Completed | Ovarian cancer|Epithelial ovarian cancer|Fallopian tube cancer | Belinostat|Paclitaxel|Carboplatin | 1/2 | Industry |
| NCT00873119 | Completed | Occult primary | Belinostat, carboplatin, paclitaxel|Carboplatin, paclitaxel | 2 | Industry |
| NCT01317927 | Active, not recruiting | Solid tumor|Hematological malignancy | Belinostat, warfarin | 1 | Industry |
| NCT01310244 | Recruiting | NSCLC | Belinostat, carboplatin, paclitaxel | 1/2 | Industry |
| NCT01090830 | Terminated | NSCLC | Belinostat, carboplatin, paclitaxel and bevacizumab | 1/2 | Other |
| NCT01839097 | Recruiting | Peripheral T-cell lymphoma | Belinostat|CHOP | 1 | Industry |
| NCT00878800 | Completed | Soft tissue sarcomas | PXD101+doxorubicin | 1/2 | Industry |
| NCT01100944 | Active, not recruiting | Thymoma|Thymic carcinoma | Belinostat|Cisplatin|Cyclophosphamide|Doxorubicin | 1/2 | NIH |
| NCT00413322 | Completed | Tumor | Belinostat|5-Flurouracil (5-FU) | 1 | Industry |
| NCT01686165 | Recruiting | Large cell lymphoma | Belinostat|Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan | 2 | Other|NIH |
| NCT00334789 | Active, not recruiting | Unspecified adult solid tumor | Belinostat|Isotretinoin|Other: pharmacological study | 1 | NIH |
| NCT01188707 | Terminated | NSCLC | Belinostat and Erlotinib | 1/2 | Other|Industry |
| NCT00926640 | Recruiting | SCLC|Malignant epithelial neoplasms | (Belinostat) (PDX101)|Cisplatin|Etoposide | 1 | NIH |
| NCT00131261 | Completed | Multiple myeloma | PXD101|Dexamethasone | 2 | Industry |